Moreover, KRAS‐ and BRAF‐mutant CRC can acquire resistance to anti‐EGFR therapies through activation of the PKC/CRAF/MEK/ERK signaling cascade, mediated by enhanced lipid metabolism. The gene discussed is KRAS; the disease is colorectal carcinoma.